Digital Health and Care Alliance opens for business; free membership available (UK)

As the dallas programme approaches its halfway point, one of its four projects, i-focus, has formed an organisation to continue the promotion of interoperability across the health & care sector beyond the end of dallas. The Alliance, with the acronym DHACA, will help NHS organisations, local authorities and third-sector providers collaborate and share information about new digital services.  This will significantly help members reduce costs, remove duplication of effort and improve support for independent living and self-management projects, resulting in much-improved patient outcomes. DHACA will operate across the full health and social care spectrum. Targeted at forward-thinking, engaged, health and care professionals as well as technology suppliers, DHACA will provide experienced assistance, trusted processes and in-depth knowledge to:

  • Define and share best practice services, technologies and business models
  • Define and share business requirements for future procurement and roadmapping
  • Better use existing investments, assets and infrastructure
  • Ensure quality, interoperability with other systems and future-proofing

Membership is currently free – more information and joining arrangements here. (Disclosure editor Charles Lowe has been recruited by ADI, as interim director of DHACA, to establish it – the medical apps work previously published on TTA will now be taken forwards in DHACA)

Driving up medical app usage in the UK – part II


This series of posts covers some work I have been doing over the past three months: attempting to answer the question of how best to improve the perception by clinicians and patients of the efficacy of health-related apps. This work has been done for the i-Focus project, part of the Technology Strategy Board’s dallas programme.

Part I attempted to summarise the EU regulations covering health-related apps. The point was made that any health-related app must comply with data protection and consumer protection requirements, irrespective of whether the risk level is sufficient for it to be classified as a ‘medical device’. Where an app is classified as a ‘medical device’ it also has to be classified so that the appropriate adjudication work can be determined for it to receive a CE mark (Class I, lowest risk, requires least investigation; Class III, highest risk, requires greatest investigation).

This post summarises the principal findings from discussions with a very wide range of potential stakeholders, (more…)